C

Cyteir Therapeutics Inc
NASDAQ:CYT

Watchlist Manager
Cyteir Therapeutics Inc
NASDAQ:CYT
Watchlist
Price: 3.01 USD Market Closed
Updated: May 17, 2024

Cyteir Therapeutics Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cyteir Therapeutics Inc
Income from Continuing Operations Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
C
Cyteir Therapeutics Inc
NASDAQ:CYT
Income from Continuing Operations
-$46.1m
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$4.9B
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$456m
CAGR 3-Years
19%
CAGR 5-Years
-40%
CAGR 10-Years
-21%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$3.8B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
$3.6B
CAGR 3-Years
10%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$3.9B
CAGR 3-Years
-1%
CAGR 5-Years
10%
CAGR 10-Years
26%

See Also

What is Cyteir Therapeutics Inc's Income from Continuing Operations?
Income from Continuing Operations
-46.1m USD

Based on the financial report for Dec 31, 2022, Cyteir Therapeutics Inc's Income from Continuing Operations amounts to -46.1m USD.

What is Cyteir Therapeutics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-45%

Over the last year, the Income from Continuing Operations growth was -9%. The average annual Income from Continuing Operations growth rates for Cyteir Therapeutics Inc have been -45% over the past three years .